cyrilzakka/clinical-trials huggingface dataset:
Lower Urinary Tract and Sexual Function in Women Following Surgery for Colorectal Disorders

This is a prevalence study evaluating lower urinary tract, prolapse, bowel, and sexual symptoms in women with a colorectal disorder who are planning to undergo surgery.

The purpose of this study is to identify the number of women who complain of lower urinary tract and bowel problems, including frequency, urgency, urinary incontinence, fecal incontinence, pain with intercourse, and other sexual problems prior to undergoing surgical management for a colorectal disorder.

Lower urinary tract symptoms, including urinary incontinence, voiding dysfunction, urgency, frequency, fecal incontinence, as well as sexual dysfunction, are directly affected by surgery for colorectal disorders. Increased risk of injury to the urinary tract is a recognized complication of pelvic surgery. These risks are related to the radical nature of pelvic surgery used to treat certain colorectal disorders, including colorectal malignancies and inflammatory bowel disease.

Few studies have looked at the incidence of lower urinary tract symptoms and sexual dysfunction in patients with colorectal conditions before and after surgery.

The primary goal of this study is to determine the prevalence of lower urinary tract symptoms in women undergoing surgery for colorectal ocnditions. We also want to describe the prevalence of these symptoms in different colorectal disorders, and how pelvic surgery impacts these symptoms.

Eligibility Criteria:
Inclusion Criteria:

* Female subjects with a diagnosis of a colorectal disorder, including rectal prolapse, inflammatory bowel disease such as Crohn's disease, Ulcerative Colitis, and colorectal malignancies planning to undergo surgery
* Females have English as a primary language

Exclusion Criteria:

* Subjects less than 18 years of age
* Subjects unable to give informed consent or complete the validated questionnaires
Mini- or Less-Open Sublay Operation (MILOS) of Incisional Hernias

Prospective non-randomized observational register study of all elective symptomatic incisional hernias operated on in the Hernia Center of Reference of Gross Sand Hospital using the novel endoscopic assisted Mini- or Less-Open Sublay technique. The data of all patients were prospectively documented in the German Hernia Registry "Herniamed". The novel MILOS-technique allows the minimal invasive implantation of large extraperitoneal meshes for the treatment of primary and secondary incisional hernias.

Prospective non-randomized observational register study of all elective symptomatic incisional hernias operated on in the Reference Hernia Center of Gross Sand Hospital between 1 January 2010 and 30 September 2015 using the novel endoscopic assisted Mini- or Less-Open Sublay technique. The novel MILOS-technique allows the minimal invasive implantation of large extraperitoneal meshes for the treatment of primary and secondary incisional hernias.The data of all patients were prospectively documented in the German Hernia Registry "Herniamed". Data privacy protection was strictly implemented according to German federal law. All patients were informed in detail about the new surgical technique, other treatment options, prospective register study with one year questionnaire follow-up, data documentation. All patients gave written consent.

A propensity score matching of all patients of the MILOS-cohort of Gross Sand Hospital with patients with comparable incisional hernias who were operated on using the laparoscopic intraperitoneal onlay mesh (IPOM) technique or open sublay technique in other institutions participating in the German Hernia Database "Herniated" was performed.

Eligibility Criteria:
Inclusion Criteria:

* All patients with symptomatic elective primary or secondary incisional hernias:
* Median incisional hernias
* Lateral incisional hernias

Exclusion Criteria:

* Emergencies
* Very large incisional hernias that required incisions larger than 12 cm
Child Pneumococcal Serotype Epidemiology In Greece

Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide. The 7-valent conjugate pneumococcal vaccine (Prevenar) has been introduced in the Greek Market in 2004. Additionally, as of 2006 Prevenar has been included in the Greek National Immunization Program.

The effect of the mass vaccination on the incidence of pneumococcal serotypes involved in the occurring invasive pneumococcal disease, is an important factor to consider for the introduction of the 13-valent pneumococcal conjugate vaccine.

open label, one group Purposive sampling of hospitalized children ≤14 years of age with confirmed IPD

Eligibility Criteria:
Inclusion Criteria:

* Children aged 14 years old or less.
* Hospitalized in a participating healthcare facility with an IPD.
* IPD will be confirmed by isolation of S. pneumoniae from a sterile body site.

Exclusion Criteria:

* Children \> 14 years of age
* Unconfirmed IPD
The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery

Many drugs have anticholinergic activity. This means that it blocks the muscarinic binding of the neurotransmitter acetylcholine.

In this study, the anticholinergic burden of the patients in the perioperative period will be calculated with the Anticholinergic Cognitive Burden Scale (ACBS) and patients with a score of 1 or above will be included in the study. Anticholinergic load of drugs used in the intraoperative period; Its effect on postoperative hospital stay, morbidity and mortality following elective heart surgery will be investigated.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective coronary artery bypass surgery
* Patients with high anticholinergic burden

Exclusion Criteria:

* All other procedures except isolated coronary bypass surgery
* Patients with low anticholinergic burden
* Patients whose records cannot be accessed through the data system
Endoscopic Full-Thickness Resection In Colon

Endoscopic full-thickness resection (EFTR) in the colon using an over-the-scope clip (OTSC) as a closure mechanism is a recent technique that allows the endoscopic resection of colonic lesions that are poor candidates for conventional endoscopic resection techniques. The aim is to study the safety and efficacy of EFTR in colon.

Early detection and endoscopic resection of early neoplastic lesions in colon can prevent the development of colon cancer.

The classic endoscopic mucosal resection technique and the submucosal dissection technique require the creation of a submucosal "cushion" by injecting crystalloid substances or colloids. However, these advanced techniques have technical limitations when facing a lesion that presents poor lifting or non-lifting at all as it might be observed in scarring or fibrotic lesions

Endoscopic full-thickness resection (EFTR) in the colon using an over-the-scope clip (OTSC) is a recent technique that does not require the injection of a submucosal solution and allows a resection of colonic lesions of up to approximately 30 mm, en bloc, allowing a correct histological study of the sample, to confirm its complete resection with adequate deep margins, evaluation of the level of invasion and lymphovascular involvement.

EFTR with OTSC allows a colonic wall full-thickness resection, by the deployment of an over-the-scope clip before the resection of the lesion to prevent perforation. The steps of the technique are: face the lesion and marking the borders, insertion of the scope with the kit (consisting of a cap with an integrated snare and OTSC), grasping and pulling the lesion into the cap, deploy the over-the-scope-clip (OTSC) and closing the integrated snare and resect.

This is a multicenter observational study on the efficacy and safety of EFTR with OTSC in colon.

The clinical, endoscopic and histological data are collected prospectively in all cases of EFTR performed in the participant centers.

Eligibility Criteria:
Inclusion Criteria:

* Adults (≥18 years) of both sexes.
* Colonic lesions less than 30mm unresectable en-bloc by other less invasive endoscopic techniques, including lesions suggestive of T1, subepithelial tumors, lesions with diverticular involvement, lesions with no-lifting signs (recurrent, incomplete prior resection or untreated).
* Patients who give their written informed consent for the procedure and for the study.

Exclusion Criteria:

* Refusal to grant informed consent.
* Neoplastic lesions of the colon with evidence of advanced stage (for example, lymph node involvement) or more than 3 cm in greatest diameter.
* Any medical, psychological, geographical, or social problem that is significant and uncontrolled that may interfere with the patient's participation in the study or that does not allow adequate follow-up and adherence to the protocol and evaluation of the results of the study.
The Effect of Verbal Feedback Given by the Educator

Purpose of the research; To examine the effect of verbal feedback given by the educator on nursing students' clinical competence, academic self-efficacy and perceived stress levels.

Hypotheses of the research; H1: Nursing students' academic self-efficacy level increases after the intervention.

H2: Nursing students' clinical self-efficacy level increases after the intervention.

H3: The level of stress perceived by nursing students decreases after the intervention.

The single-group pretest/posttest experimental study consisted of 25 nursing students.

After determining the nursing students who meet the inclusion criteria in the study, data will be collected twice: pre-test (T0) and post-intervention post-test (T1). The data collection process is as follows:

Before the intervention: The Academic Self-Efficacy Scale for Undergraduate Nursing Students, the Self-Efficacy Scale in Clinical Performance, and the Perceived Stress Scale will be administered to nursing students who give written and verbal consent to participate in the research and meet the inclusion criteria.

Intervention: During the study, the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks. Within the scope of this interview, the educator will give verbal feedback about the strengths and development aspects of the student's diagnosis, planning, implementation, evaluation stages and clinical skills in line with the nursing care plan. In addition, if there are clinical assignments (such as case analysis) given to the student, the educator will give feedback on this subject as well.

Post-intervention: Academic Self-Efficacy Scale, Clinical Performance Self-Efficacy Scale and Perceived Stress Level Scale will be administered to Undergraduate Nursing Students.

Eligibility Criteria:
Inclusion Criteria:

* a 3rd year nursing student,
* Taking part in the Mental Health and Diseases Nursing clinical internship program

Exclusion Criteria:

* Not volunteering to participate in the study
* previously participated in the Mental Health and Diseases Nursing clinical internship program
A Clinical Study on the Effect of DHA & ARA Candy on the Cognitive Improvement in Preschool Children

The goal of this interventional study is to evaluate the effectiveness of DHA (docosahexaenoic acid) \& ARA (arachidonic acid) Candy on the cognitive development of preschool children (2-6 years old). The main questions it aims to answer are:

- Does DHA \& ARA Candy improve the cognitive ability in terms of Wechsler Intelligence Scale for Children 4th edition-Chinese version (WISC-IV-Chinese)?

Researchers will administer the WISC-IV-Chinese following the guidelines strictly and analyze the score to conclude whether the DHA \& ARA is effective to improve the cognitive ability of preschool childchildren.

Participants will eat 1-2 candy (each contains 100mg DHA and 100mg ARA) daily for 4 consecutive weeks and take the WISC-IV-Chinese test for three times according to the protocol.


Eligibility Criteria:
Inclusion Criteria:

* Participants must be 2-6 years old
* Healthy children of normal development, without gender restrictions, with a male to female ratio of more than 40%;
* During the trial period, participants agree not to take any medications, supplements, or other nutritional products containing DHA and ARA;
* Parents or legal guardians (at least one party) have signed an informed consent form, voluntarily participating in this study and complying with the study design;
* Willing to not participate in other interventional nutritional studies during the trial period;
* Capable of fully understanding the nature, purpose, benefits, and potential risks and side effects of this study.

Exclusion Criteria:

* Allergic to dairy products;
* Severely intolerant to milk dairy products;
* Unable to provide written informed consent;
* During the screening period, or within the past two weeks, has used antibiotics;
* Currently taking therapeutic medications;
* The volunteer has any of the following medical histories or has been nutritionally diagnosed with any of the following diseases: significant gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory, or cardiovascular diseases, which may affect the assessment of the trial's effects;
* Suffering from any gastrointestinal dysfunction or gastrointestinal disease. For example, but not limited to: Irritable Bowel Syndrome (IBS), enteritis, ulcerative colitis, celiac disease, irritable bowel syndrome;
* Has a history of hospitalization within the past 3 months;
* According to the researcher's judgment, currently frequently using medications that may affect gastrointestinal function or the immune system.
Effect of Capnography Feedback During Cardiopulmonary Resuscitation (CPR ) on Patient's Outcome

Compare the quality performance of rescuers and resuscitation outcomes of cardiac arrest patients in both groups with and without capnography feedback

This study has done at Mashhad Ghaem Educational center. Two nurses and an anesthesia resident selected and trained according to the latest guidelines of CPR . In the control sample, with the declare of code 99 and attend the team on the patient's bedside, CPR begins and then every two minutes, return of the patient checks in the usual way. quality performance of rescuers ,Recovery or death of the patient and the result is recording. In the second phase , group members were educated how to use capnography (Comdek's MD-660P Oxi-Capnography) in CPR and guiding restoration efforts by it. with the code 99 and attend the team on the patient's bedside capnography uses and its waveforms will appear on the monitor device which is visible to all rescuers and the quality of performance is renewed based on the its guidance. The two groups patients for age, sex, initial rhythm of arrest, time of arrest until the first action, the time of arrest until the first shocks are comparing to control these factors influence on the outcome. quality performance of rescuers , resuscitation outcomes and CPR duration and relative factors in each of the groups were recorded and compared.

Eligibility Criteria:
Inclusion Criteria:

* cardiac arrest patient age more than 18

Exclusion Criteria:

* age more than 80 cardiac arrest due to pulmonary embolism
Absence of Liner Following the Selective Caries Removal (ALFSCaRe)

This randomized, multi-centric, controlled clinical trial will assess the effectiveness of a simplified restorative protocol used after the selective carious tissue removal in posterior teeth presenting deep carious lesions. Only a regular bulk-fill composite will be used in the simplified restorative protocol following the application of universal adhesive. A liner with resin-modified glass ionomer will be used over the pulpal floor before the composite placement in the control group. The longevity of restorative procedures and post-operative sensitivity were defined as the main and secondary outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Molar presenting deep carious lesion;

Exclusion Criteria:

* Non-vital teeth or teeth presenting pulpitis;
* Cavity margins in dentin;
* Presence of non-carious cervical lesions;
* The necessity of restoration involving any cusp replacement.
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.


Eligibility Criteria:
Inclusion Criteria:

* Metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy.
* Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST 1.1.

For Cohort A:

- First line metastatic colorectal cancer.

For Cohort B:

- Second line metastatic colorectal cancer that has progressed on prior chemotherapy administered for metastatic disease and which must include a fluoropyrimidine and oxaliplatin.

For Cohort C:

- Second line metastatic gastroesophageal cancer that has progressed on prior line of chemotherapy administered for metastatic disease, and which must include a platinum agent and fluoropyrimidine doublet.

For Cohort D:

- Second or third line metastatic renal cell carcinoma with a clear-cell component and has received one or two lines of treatment for metastatic disease that included an anti-angiogenic agent for at least 4 weeks with radiologic progression on that treatment.

For subjects starting from Part 1a in Cohorts A and B:

* Serum hs-CRP at screening ≥ 10 mg/L.
* Not requiring immediate initiation of anti-cancer therapy per investigator's best judgement.

For subjects starting from Part 2 in Cohort C:

- Serum hs-CRP at screening ≥ 10 mg/L.

Exclusion Criteria:

For All Cohorts:

* Currently receiving any of the prohibited medications or has contraindications as outlined in the protocol.
* Symptomatic brain metastases or brain metastases that require directed therapy (such as focal radiotherapy or surgery).
* Suspected or proven immunocompromised state, or infections (as defined in the protocol).
* Conditions that have a high risk of clinically significant bleeding after administration of anti-VEGF agents.
* Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular disease.

For Cohort D:

* Concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
* Impairment of GI function or GI disease that may significantly alter the absorption of cabozantinib.

Other protocol-defined inclusion/exclusion criteria may apply
Developing Smokers for Smoker (S4S): A Collective Intelligence Tailoring System

This study will advance computer tailoring by adapting machine learning collective intelligence algorithms that have been used outside healthcare by companies like Amazon and Google to enhance the personal relevance of the health communication.

Smoking is still the number one preventable cause of cancer death. New approaches are needed to engage smokers in the 21st century in smoking cessation. I propose to develop S4S (Smokers for Smoker), a next-generation patient-centered computer tailored health communication (CTHC) system. Unlike current rule-based CTHCs, S4S will replace rules with complex machine learning algorithms, and use the collective experiences of thousands of smokers engaged in a web-assisted tobacco intervention to enhance personally-relevant tailoring for new smokers entering the system. The investigators will adapt collective intelligence algorithms that have been used outside healthcare by companies like Amazon and Google to enhance CTHC. Using knowledge from scientific experts, current CTHC collect baseline patient "profiles" and then use expert-written, rule-based systems to tailor messages to patient subsets. Such theory-based "market segmentation has been effective in helping patients reach lifestyle goals. However, there is a natural limit in the ability of a rule-based system to truly personalize content, and adapt personalization over time. Current CTHC have reached this limit, and the investigators propose to go beyond. The investigators first aim is to develop the Web 2.0 "S4S" recommender system. The investigators second aim is to evaluate S4S within the context of a NCI funded web-assisted tobacco intervention (Decide2Quit.org).

Eligibility Criteria:
Inclusion Criteria:

* Current Smokers

Exclusion Criteria:

-
VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures.

The investigators want to verify whether the surgical outcome of vessel-sparing anastomotic repair in isolated short bulbar urethral strictures is not inferior to the surgical outcome of transecting anastomotic repair. Furthermore, the investigators compare the functional outcome of both techniques verifying if there is less erectile dysfunction after vessel-sparing anastomotic repair than after transecting anastomotic repair.

A randomized controlled trial comparing vessel-sparing anastomotic repair (vsAR) and transecting anastomotic repair (tAR) in isolated short bulbar urethral strictures (maximum 3 centimeter) for both surgical and functional outcome, to demonstrate that vsAR is not inferior to tAR regarding the surgical outcome, and to demonstrate a benefit for vsAR over tAR regarding postoperative erectile function.

Eligibility Criteria:
Inclusion Criteria:

* Voluntary signed written informed consent (according to the rules of Good Clinical Practice and national regulations)
* Male
* Age \>= 18 years
* Fit for operation, based on the surgeon's expert opinion
* Isolated short (=\< 3cm) bulbar urethral stricture confirmed by preoperative retrograde urethrography (RUG), voiding cysto-urethrography (VCUG), cystoscopy, ultrasonography or a combination of investigations
* Unique urethral stricture
* Urethral stricture =\< 3 cm
* Urethral stricture at the bulbar segment
* Patient declares that it will be possible for him to attend the follow-up consultation

Exclusion Criteria:

* Absence of signed written informed consent
* Age \<18 years
* Female patients
* Transgender patients
* Patients unfit for operation
* Concomitant urethral strictures at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck)
* Urethral strictures exceeding 3 cm
* A unique urethral stricture at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck)
* Lichen Sclerosus related strictures
* Strictures after failed hypospadias repair
* Patients with neurogenic bladder
* Shift of technique to augmented urethroplasty due to any circumstance
* History of pelvic radiation therapy
* Active treatment to enhance erectile function (such as PDE5-inhibitors and intracavernous injections) at the moment of prescreening for inclusion in this trial
* Any condition or situation, which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study
* Patient declares that it will be impossible for him to attend the follow-up consultations